Preparation of platelet pellet lysate and its use for treating neurological disorders
A neurological disease, lysate technology, applied in the field of obtaining a new type of platelet precipitation lysate, to achieve the effect of enhancing neuroprotective activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0096] The following abbreviations are used throughout the specification, drawings and claims:
[0097] BAFF: B cell activating factor;
[0098] BDNF: brain-derived neurotrophic factor;
[0099] C5 / C5a: complement component 5 / activation;
[0100] CSF: cerebrospinal fluid;
[0101] Ctrl: control;
[0102] Dkk-1: Dickkopf WNT signaling pathway inhibitor 1;
[0103] DPPIV: dipeptidyl peptidase IV;
[0104] EGF: epithelial growth factor;
[0105] EMMPRIN: extracellular matrix metalloproteinase inducer;
[0106] ENA-78: epithelial-derived neutrophil-activating peptide 78;
[0107] FGF: fibroblast growth factor;
[0108] FGF-β: Fibroblast Growth Factor-β;
[0109] Fas L: fas ligand;
[0110] G-CSF: granulocyte colony-stimulating factor;
[0111] GDF-15: growth differentiation factor 15;
[0112] HGF: hepatocyte growth factor;
[0113] IGFBP-2: insulin-like growth factor binding protein-2;
[0114] IL: interleukin;
[0115] IP-10: interferon protein 10;
[0116] I-TAC...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


